Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by ...

"I'd consider this to be the version of the game I’d have released if I had a bit more time to playtest the game thoroughly." When you purchase through links on our site, we may earn an affiliate ...

Eli Lilly has seen revenue soar thanks to its blockbuster weight loss drug portfolio. Lilly and Novo Nordisk dominate this market, which has seen high demand. Eli Lilly (NYSE: LLY) stock recently ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement ...

Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare. Lilly is close to releasing a pill form of its best-selling drug ...

The Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) sits squarely at the center of Monday's shock. The fund's top weights — Eli Lilly at 18.72% and Novo Nordisk at 13.23% — mean that more than ...

Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC.

Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.